Similar articles

• Immunologic reconstitution of patients with primary immunodeficiency diseases and cancer after treatment with thymosin.

  Goldstein AL, Thurman GB, Rossio JL, Costanzi JJ. Goldstein AL, et al. Transplant Proc. 1977 Mar;9(1):1141-4. Transplant Proc. 1977. PMID: 325742 No abstract available.
• Thymosin: basic properties and clinical application in the treatment of immunodeficiency diseases and cancer.

  Marshall GD Jr, Thurman GB, Low TL, Goldstein AL. Marshall GD Jr, et al. Recent Results Cancer Res. 1980;75:100-5. doi: 10.1007/978-3-642-81491-4_16. Recent Results Cancer Res. 1980. PMID: 6262885
• [Regular trisomy 21 and combined immunodeficiency. Ineffectiveness of thymosin].

  Calvani M, Aiuti F, Felici N, D'Amelio R, Picchio E. Calvani M, et al. Minerva Pediatr. 1979 Dec 15;31(23):1691-7. Minerva Pediatr. 1979. PMID: 162325 Italian. No abstract available.
• Thymosin: basic properties and clinical potential in the treatment of patients with immunodeficiency diseases and cancer.

  Goldstein AL. Goldstein AL. Antibiot Chemother (1971). 1978;24:47-59. doi: 10.1159/000401500. Antibiot Chemother (1971). 1978. PMID: 350140 Review. No abstract available.
• [Results and prospects of using thymosin for the purpose of regulating the immune system in different pathological processes and states].

  Grinevich IuA, Kamenets LIa. Grinevich IuA, et al. Zh Mikrobiol Epidemiol Immunobiol. 1979 Dec;(12):9-15. Zh Mikrobiol Epidemiol Immunobiol. 1979. PMID: 390944 Review. Russian. No abstract available.